Samsung Biologics Forms Strategic Manufacturing Partnership
Samsung Biologics (KRX: 207940.KS), a prominent player in global contract development and manufacturing, has recently established a major contract manufacturing partnership with an Asia-based pharmaceutical company. This agreement stands out as the largest contract signed by a single client in the company’s history.
Details of the Manufacturing Agreement
The contract, which carries a substantial value of USD 1.24 billion, will see production predominantly take place at Samsung Biologics' state-of-the-art manufacturing site in Songdo. The strategic agreement is set to run through 2037, showcasing the long-term commitment between the two companies.
Financial Growth and Contract Volume
This new deal is a significant boost to Samsung Biologics’ accumulated contracts for the year, pushing the total figure beyond USD 3.3 billion for 2024 alone. Such momentum emphasizes the company’s growing influence and capability within the biopharmaceutical manufacturing landscape.
Strategic Vision and Capacity Building
John Rim, the President and CEO of Samsung Biologics, expressed enthusiasm about this collaboration, noting its importance in expanding their biomanufacturing capacity to better serve clients’ needs. The company is committed to fostering strong, sustainable relationships that not only fulfill client requirements but also contribute to improved health outcomes for patients globally.
Global Partnerships with Top Pharmaceutical Companies
As part of its expansive growth strategy, Samsung Biologics has successfully partnered with 17 of the top 20 pharmaceutical companies worldwide. The company remains dedicated to broadening its customer base across critical regions, including plans to enhance its footprint in Japan, a market identified for its growth potential.
Investment in New Facilities and Technology
In further efforts to stay ahead in biomanufacturing, Samsung is set to finalize the construction of a dedicated Antibody-Drug Conjugate (ADC) facility by the end of this year. Additionally, a fifth manufacturing plant is anticipated to begin operations in April 2025, augmenting the existing capacity by an impressive 180 kL, thereby reaching a total of 784 kL across all five plants.
Innovative Drug Development Solutions
The company is also advancing its development of innovative Contract Development and Manufacturing Organization (CDO) platforms. These advancements are pivotal in addressing emerging health challenges while facilitating the production of complex biopharmaceuticals, including multispecific therapeutics.
About Samsung Biologics
Samsung Biologics operates as a fully integrated CDMO, providing comprehensive services from cell line development to final aseptic fill and finish. With facilities built to comply with CGMP standards, the company can accommodate a range of client needs. In pursuit of operational excellence and efficiency, Samsung Biologics has made significant investments in its global infrastructure, including a new facility focused on mRNA manufacturing.
Contact Information
For media inquiries, please contact:
Claire Kim, Head of Global Marketing and Communications
Email: cair.kim@samsung.com
Frequently Asked Questions
What is the value of the recent contract signed by Samsung Biologics?
The recent contract is valued at USD 1.24 billion, marking it as the largest contract signed with a single client.
How long will the manufacturing agreement last?
The manufacturing agreement is set to run through December 2037, indicating a long-term partnership.
What capacity expansion is Samsung Biologics planning?
Samsung Biologics will expand its manufacturing capacity by an additional 180 kL through the completion of its fifth plant, expected to be operational by April 2025.
Which companies has Samsung Biologics partnered with?
Samsung has partnered with 17 of the world's top 20 pharmaceutical companies, showcasing its extensive influence in the industry.
What types of solutions does Samsung Biologics offer?
Samsung Biologics provides end-to-end CDMO services, including development, manufacturing, and laboratory testing support for biopharmaceutical products.
